| Q73850972 | 17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects |
| Q78422416 | A New Aromatase Inhibitor, FR901537. I. Taxonomy, Fermentation, Isolation, Physicochemical Characteristics and Biological Activities. |
| Q40643488 | A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate. |
| Q30440238 | Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells |
| Q30308738 | Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients |
| Q30309688 | Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells |
| Q37622884 | Additive endocrine therapy for advanced breast cancer - back to the future |
| Q22009952 | An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens |
| Q73587646 | Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES) |
| Q44045676 | Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial |
| Q33875995 | Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells |
| Q41501630 | Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells |
| Q73574222 | Aromatase inhibitors and breast cancer |
| Q35073337 | Aromatase inhibitors for the treatment of infertility |
| Q34324837 | Aromatase inhibitors--mechanisms for non-steroidal inhibitors |
| Q41053025 | Aromatase inhibitors--mechanisms of steroidal inhibitors |
| Q44088360 | Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells |
| Q22011095 | BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells |
| Q35612285 | Biological rationale for endocrine therapy in breast cancer |
| Q36620745 | Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa |
| Q50879143 | Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. |
| Q26781860 | Celebrating 75 years of oestradiol |
| Q33995787 | Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors |
| Q35577441 | Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials |
| Q35722575 | Clinical pharmacokinetics of endocrine agents used in advanced breast cancer |
| Q72783702 | Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen |
| Q36817165 | Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation |
| Q37115216 | Clinical use of aromatase inhibitors in human breast carcinoma |
| Q35683807 | Clinical utility of exemestane in the treatment of breast cancer |
| Q77747948 | Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo |
| Q36422772 | Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study |
| Q33726204 | Comprehensive pharmacology and clinical efficacy of aromatase inhibitors |
| Q36569036 | Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth |
| Q50655532 | Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. |
| Q35012780 | Current status of estrogen receptors. |
| Q77834159 | Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers |
| Q30440243 | Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells |
| Q36895986 | Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells |
| Q34990893 | Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells |
| Q57763490 | Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang |
| Q54142148 | Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. |
| Q71702871 | Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors |
| Q46402073 | Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer |
| Q43708436 | Effect of letrozole on the lipid profile in postmenopausal women with breast cancer |
| Q72952454 | Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma |
| Q72776921 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients |
| Q44229613 | Effects of anastrozole on lipid metabolism compared with tamoxifen in rats |
| Q57108908 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature |
| Q36079441 | Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer |
| Q30429931 | Estrogen Stimulation of Cell Migration Involves Multiple Signaling Pathway Interactions |
| Q74155881 | Estrogen antagonism on T3 and growth hormone control of the liver microsomal low-affinity glucocorticoid binding site (LAGS) |
| Q28396413 | Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence |
| Q37033947 | Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies |
| Q70585764 | Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor |
| Q39013327 | Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro. |
| Q71394585 | Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma |
| Q36295053 | Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up |
| Q57082658 | Glucocorticoids and androgens up-regulate the Zn-?2-glycoprotein messenger RNA in human breast cancer cells |
| Q40394336 | Gonadotrophin-releasing hormone agonists. A guide to use and selection |
| Q44401763 | Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination |
| Q36080872 | High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa |
| Q57082654 | Hormonal Regulation of the Human Pepsinogen C Gene in Breast Cancer Cells |
| Q35802104 | Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study |
| Q33654582 | Hormonal therapy for breast cancer. An update |
| Q40877143 | Hormone therapy following breast and uterine cancer |
| Q39707882 | Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. |
| Q34392227 | Hypothalamic hormones and cancer |
| Q34941433 | Identification and assessment of endocrine disruptors: limitations of in vivo and in vitro assays |
| Q28246373 | Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusion-mediated gene transfer in human breast-cancer cells |
| Q44628026 | Identification of genes involved in growth inhibition of breast cancer cells transduced with estrogen receptor |
| Q33909035 | Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. |
| Q34987316 | In vivo transcription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide |
| Q89338758 | Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer |
| Q67589160 | Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment |
| Q71697702 | Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer |
| Q74505922 | Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists |
| Q30311195 | Inhibition of aromatase: insights from recent studies |
| Q67550875 | Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH |
| Q41014659 | Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. |
| Q41487094 | Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice |
| Q40791998 | Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators |
| Q33993658 | Is there a growing role for endocrine therapy in the treatment of breast cancer? |
| Q48216793 | LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro |
| Q41463849 | Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients |
| Q53352963 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). |
| Q41714200 | Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? |
| Q33779856 | Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis |
| Q73144794 | Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake |
| Q33993962 | Mechanisms of cyclin-dependent kinase inactivation by progestins |
| Q34132652 | Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology |
| Q36859620 | Novel endocrine therapies in breast cancer |
| Q35937856 | Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design |
| Q73016867 | Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma |
| Q36619469 | Ovarian cysts in women receiving tamoxifen for breast cancer |
| Q34880894 | Premenopausal breast cancer: chemotherapy and endocrine therapy |
| Q36277982 | Progesterone regulates the proliferation of breast cancer cells - in vitro evidence |
| Q36735932 | Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes |
| Q36101408 | Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation. |
| Q73850253 | Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions |
| Q47676755 | Receptor independent effects on DNA replication by steroids |
| Q72776902 | Regulation of aromatase expression in human tissues |
| Q40999887 | Regulation of oestrogen action: role of 17 beta-hydroxysteroid dehydrogenases. |
| Q30306356 | Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells |
| Q40908719 | Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. |
| Q33902476 | Role of the androgen receptor in human breast cancer |
| Q33339120 | Solving the puzzle of hormone-dependent breast cancer |
| Q38825609 | Steroid hormone secretion in inflammatory breast cancer cell lines |
| Q41476056 | Steroid hormones and cancer: (III) observations from human subjects |
| Q43778273 | Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples |
| Q78244539 | Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure |
| Q44454355 | Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand: [18F] propyl pyrazole triol |
| Q74072228 | Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons |
| Q44718286 | Synthetic estrogen-mediated activation of ERK 2 intracellular signaling molecule |
| Q33560136 | Systemic therapy in breast cancer: efficacy and cost utility |
| Q74741104 | Tamoxifen-induced light and electron microscopic changes in the rat testicular morphology and serum hormonal profile of reproductive hormones |
| Q80089159 | Targeted functional imaging in breast cancer |
| Q58598694 | The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast |
| Q39592732 | The endogenous progesterone metabolite, 5a-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells |
| Q40960429 | The future of antihormone therapy: innovations based on an established principle |
| Q45788428 | The oestrogen paradox: an hypothesis |
| Q34388848 | Tracking progesterone receptor-mediated actions in breast cancer |
| Q40790191 | William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis |
| Q40790184 | William L. McGuire Memorial Symposium. Estrogen receptors: ligand discrimination and antiestrogen action |
| Q35189958 | p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation |